Treatment of acromegaly with dopamine agonists

Endocrinology and Metabolism Clinics of North America

Volumn 21, Issue 3, 1992, Pages 713-735

  Jaffe, C A ^a   Barkan, A L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA; CYPROHEPTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LEVODOPA; LISURIDE; MESULERGINE; OCTREOTIDE; PERGOLIDE; PYRIDOSTIGMINE; SOMATOMEDIN C; TERGURIDE;

ACROMEGALY; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0026701677     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0889-8529(18)30210-x     Document Type: Review

References (171)

1. Adams E.F. Ghuttacharji S.C. Halliwell C.L. Effect of pancreatic growth hormone releasing factors on GH secretion by human somatotrophic pituitary tumours in cell culture Clin Endocrinol 21 1984 709 718
2. Aellig W.H. Nuesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man Int I Clin Pharmacol Biopharm 15 1977 106 112
3. Alba-Roth J. von Creytz C. Mehltretter G. Interaction of L-dopa and GHRH on GH secretion in normal men J Endocrinol Invest 12 1989 783 787
4. Anniko M. Werner S. Wersall J. Bromocriptine-induced changes in hormone secretion and cell morphology in growth hormone and prolactin producing pituitary adenomas Acta Otolaryngol 92 1981 343 355
5. Anniko M. Wersall J. Morphological changes in bromocriptine-treated pituitary tumours Acta Otolaryngol 96 1983 337 353
6. Arce V. Lima L. Lois N. Role of central dopaminergic pathways in the neural control of growth hormone secretion in normal men: Studies with metoclopramide Neuroendocrinology 53 1991 143 149
7. Bansal S. Lee L.A. Woolf P.D. Dopaminergic regulation of growth hormone (GH) secretion in normal man: Correlation of L-dopa and dopamine levels with the GH response J Clin Endocrinol Metab 53 1981 301 306
8. Barinaga M. Bilezikjian L.M. Vale W.W. Independent effects of growth hormone releasing factor on growth hormone release and gene transcription Nature 314 1985 279 281
9. Barkan A.L. Acromegaly. Diagnosis and therapy Endocrinol Metab Clin North Am 18 1989 277 310
10. Barkan A.L. Beitins I.Z. Kelch R.P. Plasma insulin-like growth factor-I/Somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion J Clin Endocrinol Metab 67 1988 69 73
11. Barkan A.L. Kelch R.P. Hopwood N.J. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995 J Clin Endocrinol Metab 66 1988 16 23
12. Barkan A.L. Shenker Y. Grekin R.J. Acromegaly due to ectopic growth hormone (GH)-releasing hormone (GHRH) production: Dynamic studies of GH and ectopic GHRH secretion J Clin Endocrinol Metab 63 1986 1057 1064
13. Barkan A.L. Stred S.E. Reno K. Increased growth hormone pulse frequency in acromegaly J Clin Endocrinol Metab 69 1989 1225 1233
14. Baumann G. Growth hormone heterogenity: Genes, isohormones, variants, and binding proteins Endocr Rev 12 1991 424 449
15. Beck-Peccoz P. Bassetti M. Spada A. Glycoprotein hormone alpha-subunit response to growth hormone (GH)-releasing hormone in patients with active acromegaly. Evidence for alpha-subunit and GH coexistence in the same tumoral cell J Clin Endocrinol Metab 61 1985 541 546
16. Belforte L. Camanni F. Chiodini P.G. Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly Acta Endocrinol 85 1977 235 248
17. Bell P.M. Atkinson A.B. Hadden D.R. Bromocriptine reduces growth hormone in acromegaly Arch Intern Med 146 1986 1145 1149
18. Benker G. Sandmann K. Tharandt L. Gel filtration studies of serum growth hormone in acromegaly following bromocriptine administration Horm Res 11 1979 151 160
19. Bennett G.W. Edwardson J.A. Marcano de Cotte M. Release of somatostatin from rat brain synaptosomes J Neurochem 32 1979 1127 1130
20. Berelowitz M. Firestone S.L. Frohman L.A. Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution Endocrinology 109 1981 714 719
21. Berelowitz M. Maeda K. Harris S. The effect of alterations in the pituitarythyroid axis on hypothalamic content and in vitro release of somatostatin-like immunoreactivity Endocrinology 107 1980 24 29
22. Berelowitz M. Szabo M. Frohman L.A. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary Science 212 1981 1279 1281
23. Berezin M. Elchalal U. Olchovsky D. Treatment of hyperprolactinemia and acromegaly with lisuride Harefuah 116 1989 634 637
24. Besser G.M. Wass J.A. Thorner M.O. Acromegaly—results of long term treatment with bromocriptine Acta Endocrinol 216 Suppl 1978 187 198
25. Besser G.M. Wass J.A. Medical management of acromegaly with bromocriptine. Effects of continuous treatment for over three years Med J Aust 2 1978 31 33
26. Boyd A.E. Lebovitz H.E. Pfeiffer J.B. Stimulation of human-growth-hormone secretion by L-dopa N Engl J Med 283 1970 1425 1429
27. Bression D. Brandi A.M. Nousbaum A. Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system J Clin Endocrinol Metab 55 1982 589 593
28. Camanni F. Massara F. Belforte L. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine J Clin Endocrinol Metab 40 1975 363 366
29. Camanni F. Picotti G.B. Massara F. Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients J Clin Endocrinol Metab 47 1978 647 652
30. Carlson H.E. Levin S.R. Braunstein G.D. Effect of bromocriptine on serum hormones in acromegaly Horm Res 19 1984 142 152
31. Cassar J. Mashiter K. Joplin G.F. Bromocriptine treatment of acromegaly Metabolism 26 1977 539 546
32. Chenette P.E. Siegel M.S. Vermesh M. Effect of bromocriptine on sperm function in vitro and in vivo Obstet Gynecol 77 1991 935 938
33. Chiba T. Chihara K. Minamitani N. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly Horm Metab Res 14 1982 57 61
34. Chihara K. Arimura A. Schally A.V. Immunoreactive somatostatin in rat hypophyseal portal blood: effects of anesthetics Endocrinology 104 1979 1434 1441
35. Chihara K. Kashio Y. Kita T. L-Dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans J Clin Endocrinol Metab 62 1986 466 473
36. Chiodini P.G. Cozzi R. Dallabonzana D. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: A comparison with bromocriptine J Clin Endocrinol Metab 64 1987 447 453
37. Chiodini P.G. Liuzzi A. Botalla L. Stable reduction of plasma GH levels during chronic administration of 2-BR-alpha-ergocryptine (CB 154) in acromegalic subjects J Clin Endocrinol Metab 40 1975 705 708
38. Ciccarelli E. Miola C. Avataneo T. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia Fertil Steril 52 1989 930 935
39. Clayton R.N. Vrionides Y. Lynch S.S. Response of acromegaly to long term bromocriptine therapy: A biochemical and clinical assessment Acta Endocrinol 89 1978 469 482
40. Cozzi R. Dallabonzana D. Oppizzi G. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly J Clin Endocrinol Metab 62 1986 601 604
41. Cronin M.J. Cheung C.Y. Wilson C.B. [3H]Spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone J Clin Endocrinol Metab 50 1980 387 391
42. Cronin M.J. Thorner M.O. Hellmann P. Bromocriptine inhibits growth hormone release from rat pituitary cells in primary culture Proc Soc Exp Biol Med 175 1984 191 195
43. Cryer P.E. Daughaday W.H. Regulation of growth hormone secretion in acromegaly J Clin Endocrinol Metab 29 1969 386 393
44. Dallabonzana D. Liuzzi A. Oppizzi G. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride J Clin Endocrinol Metab 63 1986 1002 1007
45. Dallabonzana D. Liuzzi A. Oppizzi G. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly J Endocrinol Invest 8 1985 147 151
46. Delitala G. Palermo M. Ross R. Dopaminergic and cholinergic influences on the growth hormone response to growth hormone-releasing hormone in man Neuroendocrinology 45 1987 243 247
47. Delitala G. Tomasi P. Virdis R. Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications J Endocrinol Invest 11 1988 441 462
48. Drewe J. Mazer N. Abisch E. Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation Eur J Clin Pharmacol 35 1988 535 541
49. Dunn P.J. Donald R.A. Espiner E.A. Bromocriptine suppression of plasma growth hormone in acromegaly Clin Endocrinol 7 1977 273 281
50. Esiri M.M. Bevan J.S. Burke C.W. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland J Clin Endocrinol Metab 63 1986 383 388
51. Eskildsen P.C. Hommel E. Buchhave J. The effect of a new ergoline derivative, CU 32-085, in the treatment of acromegaly. A controlled study Clin Endocrinol 22 1985 189 200
52. Eskildsen P.C. Lund B. Sorensen O.H. Acromegaly and vitamin D metabolism: Effect of bromocriptine treatment J Clin Endocrinol Metab 49 1979 484 486
53. Fanghanel-S G. Larraza O. Arauco R. Serum growth hormone and ultrastructural studies of adenohypophysial tissue in bromocriptine treated acromegalic patients Clin Endocrinol 9 1978 289 296
54. Ferrari C. Paracchi A. Romano C. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients Clin Endocrinol 29 1988 467 476
55. Fluckiger E. Wagner H.R. 2-Br-a-ergokryptin: Beeinflussung von fertilitat und lakation bei der ratte Experientia 24 1968 1130 1131
56. Frohman L.A. Diseases of the anterior pituitary Felig P. Baxter J.P. Broadus A.E. Endocrinology and Metabolism 1987 McGraw-Hill New York 283 284
57. Fukata J. Diamond D.J. Martin J.B. Effects of rat growth hormone (rGH)-releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitary cells Endocrinology 117 1985 457 467
58. Garcia Lopez J.M. De la Fuente A. Tome M.A. Acromegaly and insulin resistance: A case study Acta Endocrinol 111 1986 445 451
59. Ghigo E. Bellone J. Imperiale E. Pyridostigmine potentiates L-dopa—but not arginine-and galanin-induced growth hormone secretion in children Neuroendocrinology 52 1990 42 45
60. Gross D.J. Halperin Y. Gomori J.M. Bromocriptine treatment of acromegaly: Possible dose dependency of the tumor size-reducing effect Isr J Med Sei 25 1989 256 260
61. Grossman A. Ross R. Wass J.A. Depot-bromocriptine treatment for prolactinomas and acromegaly Clin Endocrinol 24 1986 231 238
62. Halperin I. Rodriguez M.D. Cardenal C. Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine J Endocrinol Invest 10 1987 277 282
63. Halse J. Harris A.G. Kvistborg A. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: Clinical and biochemical effects J Clin Endocrinol Metab 70 1990 1254 1261
64. Halse J. Haugen H.N. Böhmer T. Bromocriptine treatment in acromegaly: Clinical and biochemical effects Acta Endocrinol 86 1977 464 472
65. Hanew K. Sasaki A. Sato S. Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly J Clin Endocrinol Metab 64 1987 255 260
66. Hanew K. Sasaki A. Mouri T. Plasma growth hormone and prolactin responses to TRH and arginine given before and during bromocriptine therapy to patients with acromegaly Acta Endocrinol 95 1980 298 307
67. Hanew K. Sugawara A. Shimizu Y. The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly Endocrinol Jpn 36 1989 429 438
68. Hanew K, Utsami A, Sugawara A, et al: Pyridostigmine failed to enhance the TSH and GH responses to TRH and GHRH in patients with acromegaly [abstract 221]. In 73rd Annual Meeting of The Endocrine Society, Washington, DC, 1991
69. Heidvall K. Hulting A.L. Rapid progression of a growth hormone producing tumour during dopamine agonist treatment Br Med J 294 1987 546 547
70. Hizuka N. Hendricks C.M. Roth J. Failure of bromocriptine to alter the qualitative characteristics of human growth hormone in acromegaly Metabolism 33 1984 582 584
71. Hofland L.J. van Koetsveld P.M. Verleun T.M. Glycoprotein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: Correlation with GH release Clin Endocrinol 30 1989 601 611
72. Holdaway I.M. Frengley P.A. Scott D.J. Bromoergocryptin treatment of acromegaly persisting following conventional therapy Clin Endocrinol 8 1978 45 54
73. Holness R.O. Shlossberg A.H. Heffernan L.P. Cerebrospinal fluid rhinorrhea caused by bromocriptine therapy of prolactinoma Neurology 34 1984 111 113
74. Ishibashi M. Yamaji T. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture J Clin Invest 73 1984 66 78
75. Ishibashi M. Yamaji T. Takaku F. Secretion of glycoprotein hormone alpha-subunit by pituitary tumors J Clin Endocrinol Metab 64 1987 1187 1193
76. Jordan V. Dieguez C. Lafaffian I. Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29 Clin Endocrinol 24 1986 291 298
77. Jordan V. Dieguez C. Valcavi R. Lack of effect of muscarinic cholinergic blockade on the GH responses to GRF 1-29 and TRH in acromegalic subjects Clin Endocrinol 24 1986 415 420
78. Kakucska I. Makara G.B. Various putative neurotransmitters affect growth hormone (GH) release in rats with anterolateral hypothalamic deafferentation of the medial basal hypothalamus: Evidence for mediation by a GH-releasing factor Endocrinology 113 1983 318 323
79. Karashima T. Kato K. Nawata H. Long-term bromocriptine therapy and predictive tests in acromegaly Endocrinol Jpn 33 1986 163 167
80. Katz E. Schran H.F. Adashi E.Y. Successful treatment of a prolactin-producing pituitary macroadenoma with intra vaginal bromocriptine mesylate: A novel approach to intolerance of oral therapy Obstet Gynecol 73 1989 517 520
81. Kendall-Taylor P. Upstill-Goddard G. Cook D. Longterm pergolide treatment of acromegaly Clin Endocrinol 19 1983 711 719
82. Kitajima N. Chihara K. Abe H. Effects of dopamine on immunoreactive growth hormone-releasing factor and somatostatin secretion from rat hypothalamic slices perifused in vitro Endocrinology 124 1989 69 76
83. Kleinberg D.L. Boyd A.E.B. Wardlaw S. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone N Engl J Med 309 1983 704 709
84. Kletzky O.A. Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia Fertil Steril 51 1989 269 272
85. Kocijancic A. Prezelj J. Vrhovec I. Parlodel LAR in the treatment of macroprolactinomas Acta Endocrinol 122 1990 272 276
86. Lamberts S.W. Klijn J.G. van Vroonhoven C.C. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly Acta Endocrinol 103 1983 446 450
87. Lamberts S.W. Liuzzi A. Chiodini P.G. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly Eur J Clin Invest 12 1982 151 155
88. Lamberts S.W. Verleun T. Hofland L. A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients Clin Endocrinol 27 1987 11 23
89. Lindholm J. Riishede J. Vestergaard S. No effect of bromocriptine in acromegaly: A controlled trial N Engl J Med 304 1981 1450 1454
90. Lindstrom P. Ohlsson L. Effects of 5-hydroxytryptamine, dopamine, and aromatic L-amino acids on growth hormone (GEI)-releasing factor-stimulated GH release in rat anterior pituitaries Endocrinology 120 1987 780 784
91. Liuzzi A. Chiodini P.G. Botalla L. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration J Clin Endocrinol Metab 38 1974 910 912
92. Liuzzi A. Chiodini P.G. Botalla L. Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: Homogeneity in the two responses J Clin Endocrinol Metab 39 1974 871 876
93. Liuzzi A. Chiodini P.G. Botalla L. Inhibitory effect of L-Dopa on GH release in acromegalic patients J Clin Endocrinol Metab 35 1972 941 943
94. Lundin L. Ljunghall S. Wide L. Bromocriptine therapy in eleven patients with acromegaly Acta Endocrinol 216 Suppl 1978 207 216
95. Macfarlane I.A. Beardwell C.G. Shalet S.M. Glycoprotein hormone alpha subunit secretion by pituitary adenomas: Influence of external irradiation Clin Endocrinol 13 1980 215 222
96. Maneschi F. Reappraisal of bromocriptine treatment for acromegaly Horm Res 12 1980 191 205
97. Marcovitz S. Goodyer C.G. Guyda H. Comparative study of human fetal, normal adult, and somatotropic adenoma pituitary function in tissue culture J Clin Endocrinol Metab 54 1982 6 16
98. Marek J. Bauer J. Sramkova J. Terguride in the treatment of hyperprolactinemia and acromegaly Cas Lek Cesk 125 1986 100 105
99. Marek J. Sramkova J. Schullerova M. Long-term treatment of acromegaly with lisuride: Differences of effect on growth hormone and somatomedin Endokrinologie 78 1981 175 185
100. Mars H. Genuth S.M. Potentiation of levodopa stimulation of human growth hormone by systemic decarboxylase inhibition Clin Pharmacol Ther 14 1973 390 539
101. Massara F. Ghigo E. Molinatti P. Potentiation of cholinergic tone by pyridostigmine bromide reinstates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man Acta Endocrinol 113 1986 12 16
102. Maurer G. Schreier E. Delaborde S. Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism Eur J Drug Metab Pharmacokinet 8 1983 51 62
103. McGregor A.M. Scanlon M.F. Hall R. Effects of bromocriptine on pituitary tumour size Br Med J 2 1979 700 703
104. Melmed S. Ziel F.H. Braunstein G.D. Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor J Clin Endocrinol Metab 67 1988 395 399
105. Miki N. Ono M. Shizume K. Withdrawal of endogenous somatostatin induces secretion of growth hormone-releasing factor in rats J Endocrinol 117 1988 245 252
106. Miller W.T.J. Drug-related pleural and mediastinal disorders J Thorac Imaging 6 1991 36 51
107. Möller D.E. Moses A.C. Jones K. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion J Clin Endocrinol Metab 68 1989 499 504
108. Moses A.C. Molitch M.E. Sawin C.T. Bromocriptine therapy in acromegaly: Use in patients resistant to conventional therapy and effect on serum levels of somato-medin-C J Clin Endocrinol Metab 53 1981 752 758
109. Mountcastle R.B. Roof B.S. Mayfield R.K. Pituitary adenocarcinoma in an acromegalic patient: Response to bromocriptine and pituitary testing: A review of the literature on 36 cases of pituitary carcinoma Am J Med Sei 298 1989 109 118
110. Muller E.E. Panerai A.E. Cocchi D. Endocrine profile of ergot alkaloids Life Sei 21 1977 1545 1558
111. Musset F. Bertrand P. Kordon C. Differential coupling with pertussis toxin-sensitive G proteins of dopamine and somatostatin receptors involved in regulation of adenohypophyseal secretion Mol Cell Endocrinol 73 1990 1 10
112. Nakagawa K. Obara T. Failure of growth hormone-suppressing agents to affect TSH-releasing hormone-and LH-releasing hormone-induced growth hormone release in acromegaly J Clin Endocrinol Metab 44 1977 189 193
113. Negro-Vilar A. Ojeda S.R. Arimura A. Dopamine and norepinephrine stimulate somatostatin release by median eminence fragments in vitro Life Sei 23 1978 1493 1497
114. Nortier J.W. Croughs R.J. Thijssen J.H. Bromocriptine therapy in acromegaly: Effects on plasma GH levels, somatomedin-C levels and clinical activity Clin Endocrinol 22 1985 209 217
115. Nortier J.W. Croughs R.J. Donker G.H. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests Acta Endocrinol 106 1984 175 183
116. Nortier J.W. Croughs R.J. Donker G.H. Changes of molecular forms of growth hormone in bromocriptine treated acromegaly in relation to changes of somatomedin-C and clinical response Acta Endocrinol 108 1985 145 150
117. Oppizzi G. Liuzzi A. Chiodini P. Dopaminergic treatment of acromegaly: Different effects on hormone secretion and tumor size J Clin Endocrinol Metab 58 1984 988 992
118. Oppizzi G. Petroncini M.M. Dallabonzana D. Relationship between somatomedin-C and growth hormone levels in acromegaly: Basal and dynamic evaluation J Clin Endocrinol Metab 63 1986 1348 1353
119. Page M.D. Dieguez C. Valcavi R. Growth hormone (GH) responses to arginine and L-dopa alone and after GHRH pretreatment Clin Endocrinol 28 1988 551 558
120. Parkes D. Bromocriptine Adv Drug Res 12 1977 247 344
121. Pelkonen R. Ylikahri R. Karonen S.L. Bromocriptine treatment of patients with acromegaly resistant to conventional therapy Clin Endocrinol 12 1980 219 224
122. Plotsky P.M. Vale W. Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat Science 230 1985 461 463
123. Popovic V. Micic D. Nesovic M. Chronic bromocriptine treatment and glucose intolerance in acromegaly Exp Clin Endocrinol 85 1985 351 357
124. Quabbe H.J. Treatment of acromegaly by trans-sphenoidal operation, 90-yttrium implantation and bromocriptine: Results in 230 patients Clin Endocrinol 16 1982 107 119
125. Rail T.W. Oxytocin, prostaglandins, ergot alkaloids, and other drugs; tocolytic agents Goodman-Gilman A. Rail T.W. Nies A.S. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics 1990 Pergamon Press Elmsford, NY 939 947
126. Richardson S.B. Nguyen T. Hollander C.S. Dopamine stimulates somatostatin release from perifused hypothalamic cells Am J Physiol 244 1983 E560 E566
127. Roelfsema F. Goslings B.M. Frölich M. The influence of bromocriptine on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegaly Clin Endocrinol 11 1979 235 244
128. Ross R.J. Tsagarakis S. Grossman A. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: Studies with pyridostigmine and GHRH Clin Endocrinol 27 1987 727 733
129. Ruch A. Duhring J.L. Postpartum myocardial infarction in a patient receiving bromocriptine Obstet Gynecol 74 1989 448 451
130. Sachdev Y. Gomez-Pan A. Tunbridge W.M. Bromocriptine therapy in acromegaly Lancet 2 1975 1164 1168
131. Salti I.S. Istfan N. Bromocriptine fails to stop growth of eosinophilic adenomas in acromegaly N Engl J Med 301 1979 386 [letter]
132. Schwinn G. Dirks H. McIntosh C. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months Eur J Clin Invest 7 1977 101 107
133. Serri O. Somatotroph responsiveness to low dose dopamine infusion in normal subjects and acromegalic patients Neuroendocrinology 42 1986 475 480
134. Serri O. Deslauriers N. Brazeau P. Dual action of dopamine on growth hormone release in vitro Neuroendocrinology 45 1987 363 367
135. Serri O. Marchisio A.M. Collu R. Dopaminergic binding sites in human pituitary adenomas other than prolactinomas Horm Res 19 1984 97 102
136. Shenoy R.S. Ettigi P. Johnson C.H. Bromocriptine in the treatment of galactorrhea caused by haloperidol: A case study J Clin Psychopharmacol 3 1983 187 188
137. Sitland-Marken P.A. Wells B.G. Froemming J.H. Psychiatric applications of bromocriptine therapy J Clin Psychiatry 51 1990 68 82
138. Sonksen D.H. Greenwood F.C. Ellis J.T. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment J Clin Endocrinol Metab 27 1967 1418 1430
139. Sopwith A.M. Penny E.S. Grossman A. Normal circulating immunoreactive growth hormone releasing factor (hGRF) concentrations in patients with functional hypothalamic hGRF deficiency Clin Endocrinol 24 1986 395 400
140. Spada A. Sartorio A. Bassetti M. In vitro effect of dopamine on growth hormone (GH) release from human GH-secreting pituitary adenomas J Clin Endocrinol Metab 55 1982 734 740
141. Spark R.F. Baker R. Bienfang D.C. Bromocriptine reduces pituitary tumor size and hypersecretion: Requiem for pituitary surgery? JAMA 247 1982 311 316
142. Summers V.K. Hipkin L.J. Diver M.H. Treatment of acromegaly with bromo-cryptine J Clin Endocrinol Metab 40 1975 904 906
143. Takahashi T. Kuwayama A. Katoh T. Histological changes and operative findings of pituitary adenomas after bromocriptine treatment Nippon Naibunpi Gakkai Zasshi 62 1986 1336 1351
144. Tannenbaum G.S. Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion Endocrinology 115 1984 1952 1957
145. Thorner M.O. Besser G.M. Wass J.A. Bromocriptine in acromegaly N Engl J Med 305 1981 1092 [letter]
146. Thorner M.O. Chait A. Aitken M. Bromocriptine treatment of acromegaly Br Med J 1 1975 299 303
147. Thorner M.O. Fluckiger E. Caine D.B. Adverse reactions to bromocriptine Bromocriptine: A Clinical and Pharmacological Review 1980 Raven Press New York 150 153
148. Thorner M.O. Perryman R.L. Cronin M.J. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor J Clin Invest 70 1982 965 977
149. Thorner M.O. Schran H.F. Evans W.S. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after actue and chronic administration of bromocriptine J Clin Endocrinol Metab 50 1980 1026 1033
150. Tolis G. Pinter E.J. Friesen H.G. The acute effect of 2-bromo-a-ergocryptine (CB-154) on anterior pituitary hormones and free fatty acids in man Int J Clin Pharmacol Biopharm 12 1975 281 283
151. Turkalj I. Braun P. Krupp P. Surveillance of bromocriptine in pregnancy JAMA 247 1982 1589 1591
152. Turner T.H. Cookson J.C. Wass J.A. Psychotic reactions during treatment of pituitary tumours with dopamine agonists Br Med J 289 1984 1101 11103
153. van’t Verlaat J.W. Lancranjan I. Hendriks M.J. Primary treatment of macroprolactinomas with Parlodel LAR Acta Endocrinol 119 1988 51 55
154. Vance M.L. Kaiser D.L. Frohman L.A. Role of dopamine in the regulation of growth hormone secretion: Dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man J Clin Endocrinol Metab 64 1987 1136 1141
155. Verde G. Chiodini P.G. Liuzzi A. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states J Endocrinol Invest 3 1980 405 414
156. Vermesh M. Fossum G.T. Kletzky O.A. Vaginal bromocriptine: Pharmacology and effect on serum prolactin in normal women Obstet Gynecol 72 1988 693 698
157. Wass JAH, Charlesworth M, Kingsley DPE, et al: A prospective trial of bromocriptine in the treatment of growth hormone secreting tumors [abstract 2677]. In Seventh International Congress of Endocrinology, Quebec City, Canada, 1984
158. Wass J.A. Clemmons D.R. Underwood L.E. Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly Clin Endocrinol 17 1982 369 377
159. Wass J.A. Cudworth A.G. Bottazzo G.F. An assessment of glucose intolerance in acromegaly and its response to medical treatment Clin Endocrinol 12 1980 53 59
160. Wass J.A. Moult P.J. Thorner M.O. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy Lancet 2 1979 66 69
161. Wass J.A. Thorner M.O. Besser G.M. Gastrointestinal bleeding in patients on bromocriptine Lancet 2 1976 851 [letter]
162. Wass J.A. Thorner M.O. Besser G.M. Digital vasospasm with bromocriptine Lancet 1 1976 1135 [letter]
163. Wass J.A. Thorner M.O. Morris D.V. Long-term treatment of acromegaly with bromocriptine Br Med J 1 1977 875 878
164. Wass J.A.H. Williams J. Charlesworth M.M. Bromocriptine in management of large pituitary tumors Br Med J 284 1982 1908
165. Wehrenberg W.B. Ling N. Bohlen P. Physiological roles of somatocrinin and somatostatin in the regulation of growth hormone secretion Biochem Biophys Res Commun 109 1982 562 567
166. Weil C. The safety of bromocriptine in hyperprolactinaemic female infertility: A literature review Curr Med Res Opin 10 1986 172 195
167. Werner S. Hall K. Sjoberg H.E. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin Acta Endocrinol 216 Suppl 1978 199 206
168. Wilson J.D. Newcombe R.L. Long F.L. Cerebrospinal fluid rhinorrhoea during treatment of pituitary tumours with bromocriptine Acta Endocrinol 103 1983 457 460
169. Wollesen F. Andersen T. Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment Ann Intern Med 96 1982 281 286
170. Zeitler P. Vician L. Chowen-Breed J.A. Regulation of somatostatin and growth hormone-releasing hormone gene expression in the rat brain Metabolism 39 1990 46 49
171. Ziemer D.C. Dunlap D.B. Relief of sleep apnea in acromegaly by bromocriptine Am J Med Sei 295 1988 49 51